<?xml version='1.0' encoding='utf-8'?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2011//EN" "http://www.ncbi.nlm.nih.gov/entrez/query/DTD/pubmed_110101.dtd">
<pubmedarticleset>
 <pubmedarticle>
  <medlinecitation owner="NLM" status="MEDLINE">
   <pmid version="1">
    11939810
   </pmid>
   <datecreated>
    <year>
     2002
    </year>
    <month>
     04
    </month>
    <day>
     09
    </day>
   </datecreated>
   <datecompleted>
    <year>
     2002
    </year>
    <month>
     06
    </month>
    <day>
     04
    </day>
   </datecompleted>
   <daterevised>
    <year>
     2008
    </year>
    <month>
     03
    </month>
    <day>
     17
    </day>
   </daterevised>
   <article pubmodel="Print">
    <journal>
     <issn issntype="Print">
      0003-987X
     </issn>
     <journalissue citedmedium="Print">
      <volume>
       138
      </volume>
      <issue>
       4
      </issue>
      <pubdate>
       <year>
        2002
       </year>
       <month>
        Apr
       </month>
      </pubdate>
     </journalissue>
     <title>
      Archives of dermatology
     </title>
     <isoabbreviation>
      Arch Dermatol
     </isoabbreviation>
    </journal>
    <articletitle>
     Successful treatment of acne vulgaris using a new method: results of a randomized vehicle-controlled trial of short-contact therapy with 0.1% tazarotene gel.
    </articletitle>
    <pagination>
     <medlinepgn>
      481-9
     </medlinepgn>
    </pagination>
    <abstract>
     <abstracttext label="CONTEXT" nlmcategory="BACKGROUND">
      Short-contact application of 0.1% tazarotene gel for acne was devised to minimize local adverse effects. Its efficacy and safety are unknown.
     </abstracttext>
     <abstracttext label="OBJECTIVES" nlmcategory="OBJECTIVE">
      To assess acne improvement and tolerability during 12 weeks of short-contact treatment with 0.1% tazarotene gel vs a nonmedicated gel control.
     </abstracttext>
     <abstracttext label="DESIGN" nlmcategory="METHODS">
      A randomized, masked, vehicle-controlled trial.
     </abstracttext>
     <abstracttext label="SETTING" nlmcategory="METHODS">
      Outpatient facilities at an urban medical school and an affiliated suburban office practice.
     </abstracttext>
     <abstracttext label="PARTICIPANTS" nlmcategory="METHODS">
      Ninety-nine volunteers with facial acne were enrolled; 81 completed the study.
     </abstracttext>
     <abstracttext label="INTERVENTION" nlmcategory="METHODS">
      Thirty-three patients were randomly assigned to each of 3 groups: T + T applied 0.1% tazarotene gel twice daily, T + V applied 0.1% tazarotene gel once daily and vehicle gel once daily, and V + V applied vehicle gel twice daily. Patients adjusted the contact period as tolerated, between 30 seconds and 5 minutes per application.
     </abstracttext>
     <abstracttext label="MAIN OUTCOME MEASURES" nlmcategory="METHODS">
      Acne efficacy by reduction in acne lesions, treatment success (50%-100% improvement in global response to treatment) and improvement in overall disease severity. Local adverse effects, scored from none to severe.
     </abstracttext>
     <abstracttext label="RESULTS" nlmcategory="RESULTS">
      By week 12, T + T and T + V achieved significantly greater improvement in acne than V + V based on mean percentage reduction in noninflammatory lesions (46% and 41% vs 2%; P =.002) and inflammatory lesions (38% and 34% vs 9%; P =.01), percentage of treatment successes (64% and 61% vs 15%; P&lt;.001), and reduction in overall disease severity (30% and 29% vs 3%; P&lt;.001). Local adverse effects did not differ significantly among the 3 groups after week 4.
     </abstracttext>
     <abstracttext label="CONCLUSION" nlmcategory="CONCLUSIONS">
      Short-contact 0.1% tazarotene gel therapy is a safe and effective new method of acne treatment.
     </abstracttext>
    </abstract>
    <affiliation>
     Department of Dermatology, Mount Sinai School of Medicine, New York, NY, USA.
    </affiliation>
    <authorlist completeyn="Y">
     <author validyn="Y">
      <lastname>
       Bershad
      </lastname>
      <forename>
       Susan
      </forename>
      <initials>
       S
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Kranjac Singer
      </lastname>
      <forename>
       Giselle
      </forename>
      <initials>
       G
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Parente
      </lastname>
      <forename>
       Janice E
      </forename>
      <initials>
       JE
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Tan
      </lastname>
      <forename>
       Mei-Heng
      </forename>
      <initials>
       MH
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Sherer
      </lastname>
      <forename>
       Daniel W
      </forename>
      <initials>
       DW
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Persaud
      </lastname>
      <forename>
       Andrea N
      </forename>
      <initials>
       AN
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Lebwohl
      </lastname>
      <forename>
       Mark
      </forename>
      <initials>
       M
      </initials>
     </author>
    </authorlist>
    <language>
     eng
    </language>
    <publicationtypelist>
     <publicationtype>
      Clinical Trial
     </publicationtype>
     <publicationtype>
      Journal Article
     </publicationtype>
     <publicationtype>
      Randomized Controlled Trial
     </publicationtype>
     <publicationtype>
      Research Support, Non-U.S. Gov't
     </publicationtype>
    </publicationtypelist>
   </article>
   <medlinejournalinfo>
    <country>
     United States
    </country>
    <medlineta>
     Arch Dermatol
    </medlineta>
    <nlmuniqueid>
     0372433
    </nlmuniqueid>
    <issnlinking>
     0003-987X
    </issnlinking>
   </medlinejournalinfo>
   <chemicallist>
    <chemical>
     <registrynumber>
      0
     </registrynumber>
     <nameofsubstance>
      Gels
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      0
     </registrynumber>
     <nameofsubstance>
      Nicotinic Acids
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      0
     </registrynumber>
     <nameofsubstance>
      Retinoids
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      118292-40-3
     </registrynumber>
     <nameofsubstance>
      tazarotene
     </nameofsubstance>
    </chemical>
   </chemicallist>
   <citationsubset>
    AIM
   </citationsubset>
   <citationsubset>
    IM
   </citationsubset>
   <meshheadinglist>
    <meshheading>
     <descriptorname majortopicyn="N">
      Acne Vulgaris
     </descriptorname>
     <qualifiername majortopicyn="Y">
      drug therapy
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Adolescent
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Adult
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Child
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Female
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Gels
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Humans
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Male
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Nicotinic Acids
     </descriptorname>
     <qualifiername majortopicyn="Y">
      administration &amp; dosage
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Remission Induction
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Retinoids
     </descriptorname>
     <qualifiername majortopicyn="Y">
      administration &amp; dosage
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Time Factors
     </descriptorname>
    </meshheading>
   </meshheadinglist>
  </medlinecitation>
  <pubmeddata>
   <history>
    <pubmedpubdate pubstatus="pubmed">
     <year>
      2002
     </year>
     <month>
      4
     </month>
     <day>
      10
     </day>
     <hour>
      10
     </hour>
     <minute>
      0
     </minute>
    </pubmedpubdate>
    <pubmedpubdate pubstatus="medline">
     <year>
      2002
     </year>
     <month>
      6
     </month>
     <day>
      5
     </day>
     <hour>
      10
     </hour>
     <minute>
      1
     </minute>
    </pubmedpubdate>
    <pubmedpubdate pubstatus="entrez">
     <year>
      2002
     </year>
     <month>
      4
     </month>
     <day>
      10
     </day>
     <hour>
      10
     </hour>
     <minute>
      0
     </minute>
    </pubmedpubdate>
   </history>
   <publicationstatus>
    ppublish
   </publicationstatus>
   <articleidlist>
    <articleid idtype="pubmed">
     11939810
    </articleid>
    <articleid idtype="pii">
     dst10056
    </articleid>
   </articleidlist>
  </pubmeddata>
 </pubmedarticle>
</pubmedarticleset>

